New drug combo aims to tackle Hard-to-Treat myeloma
NCT ID NCT07084896
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two drugs, belantamab mafodotin and nirogacestat, in people with multiple myeloma that has returned or not responded to at least three prior treatments. The goal is to find a safe dose and see how well the combination shrinks tumors. About 106 adults are taking part in this early-phase trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
belantamab mafodotin and nirogacestat
What this could lead to
If it works, this combination could offer a new treatment option for people with multiple myeloma that has stopped responding to other therapies.
What could go wrong
This is an early-phase trial with only 106 participants, so results may not apply to everyone. Side effects like low blood counts and eye problems are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
238995
Atlanta, Georgia, 30322, United States
-
239015
Madison, Wisconsin, 53792, United States
-
240593
Boston, Massachusetts, 02215, United States
-
251164
Grand Rapids, Michigan, 49546, United States
-
GSK Investigational Site
Fitzroy, Victoria, 3065, Australia
-
GSK Investigational Site
Vancouver, British Columbia, V5Z1M9, Canada
-
GSK Investigational Site
Halifax, Nova Scotia, B3H 1V7, Canada
-
GSK Investigational Site
Lille, 59037, France
-
GSK Investigational Site
Villejuif, 94805, France
-
GSK Investigational Site
Frankfurt, 60590, Germany
-
GSK Investigational Site
Kiel, 24105, Germany
-
GSK Investigational Site
Leipzig, 04103, Germany
-
GSK Investigational Site
Athens, 11528, Greece
-
GSK Investigational Site
Utrecht, 3584 CX, Netherlands
-
GSK Investigational Site
Oslo, 0450, Norway
-
GSK Investigational Site
Katowice, 40-519, Poland
-
GSK Investigational Site
Lodz, 93-513, Poland
-
GSK Investigational Site
Lublin, 20-081, Poland
-
GSK Investigational Site
Moscow, 125284, Russia
-
GSK Investigational Site
Incheon, 21565, South Korea
-
GSK Investigational Site
Seoul, 06351, South Korea
-
GSK Investigational Site
Seoul, 06591, South Korea
-
GSK Investigational Site
Ulsan, 44033, South Korea
-
GSK Investigational Site
Badalona, 08916, Spain
-
GSK Investigational Site
Madrid, 28041, Spain
-
GSK Investigational Site
Madrid, 31008, Spain
-
GSK Investigational Site
Pozuelo de AlarcOn Madr, 28223, Spain
-
GSK Investigational Site
Falun, SE-791 82, Sweden
-
GSK Investigational Site
Stockholm, SE-141 86, Sweden